Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Translation of genetic association signals into molecular mechanisms for diabetes has been slow. The glucokinase regulatory protein (GKRP; gene symbol GCKR) P446L variant, associated with inverse modulation of glucose- and lipid-related traits, has been shown to alter the kinetics of glucokinase (GCK) inhibition. As GCK inhibition is associated with nuclear sequestration, we aimed to determine whether this variant also alters the direct interaction between GKRP and GCK and their intracellular localisation. METHODS: Fluorescently tagged rat and human wild-type (WT)- or P446L-GCKR and GCK were transiently transfected into HeLa cells and mouse primary hepatocytes. Whole-cell and nuclear fluorescence was quantified in individual cells exposed to low- or high-glucose conditions (5.5 or 25 mmol/l glucose, respectively). Interaction between GCK and GKRP was measured by sensitised emission-based fluorescence resonance energy transfer (FRET) efficiency. RESULTS: P446L-GKRP had a decreased degree of nuclear localisation, ability to sequester GCK and direct interaction with GCK as measured by FRET compared with WT-GKRP. Decreased interaction was observed between WT-GKRP and GCK at high compared with low glucose, but not between P446L-GKRP and GCK. Rat WT-GKRP and P446L-GKRP behaved quite differently: both variants responded to high glucose by diminished sequestration of GCK but showed no effect of the P446L variant on nuclear localisation or GCK sequestration. CONCLUSIONS/INTERPRETATION: Our study suggests the common human P446L-GKRP variant protein results in elevated hepatic glucose uptake and disposal by increasing active cytosolic GCK. This would increase hepatic lipid biosynthesis but decrease fasting plasma glucose concentrations and provides a potential mechanism for the protective effect of this allele on type 2 diabetes risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shaner, N. C., Campbell, R. E., Steinbach, P. A., Giepmans, B. N. G., Palmer, A. E., & Tsien, R. Y. (2004) · Nature Biotechnology · doi:10.1038/nbt1037 · Cited by 4,619
Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., & Manolio, T. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903103106 · Cited by 4,013
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 1×
“The glucose-lowering leucine allele is also associated with decreased fasting insulin, HOMAestimated insulin resistance and reduction of type 2 diabetes risk [10] but increased triacylglycerol and total cholesterol levels [11].”
BackgroundSelf-citationNew genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
DIAGRAM Consortium, Dupuis, J., GIANT Consortium, Global BPgen Consortium, Anders Hamsten on behalf of Procardis Consortium, the MAGIC investigators, Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.520 · Cited by 2,166
Self-citationGenomics, type 2 diabetes, and obesity
McCarthy, M. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906948 · Cited by 938
Beer, N. L., Tribble, N. D., McCulloch, L. J., Roos, C., Johnson, P. R. V., Orho-Melander, M., & Gloyn, A. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp357 · Cited by 401 · cited 8×
“This is consistent with previous studies that have established important speciesspecific differences in both the regulation of human and rat GKRP by F6P and the impact of the P446L variant on this regulation [12–14].”
BackgroundMethodInfluentialSelf-citation
Cited by
The trans-ancestral genomic architecture of glycemic traits
Chen, J., Spracklen, C. N., Marenne, G., Varshney, A., Corbin, L. J., Luan, J., Willems, S. M., Wu, Y., Zhang, X., Horikoshi, M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00852-9 · Cited by 793
Self-citationAnstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.003 · Cited by 499
Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci
Stender, S., Kozlitina, J., Nordestgaard, B. G., Tybjærg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2017) · Nature Genetics · doi:10.1038/ng.3855 · Cited by 400
An update on the genetics of hyperuricaemia and gout
Major, T. J., Dalbeth, N., Stahl, E. A., & Merriman, T. R. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0004-x · Cited by 332
Stančáková, A., Civelek, M., Saleem, N. K., Soininen, P., Kangas, A. J., Cederberg, H., Paananen, J., Pihlajamäki, J., Bonnycastle, L. L., Morken, M. A., et al. (2012) · Diabetes · doi:10.2337/db11-1378 · Cited by 279
Self-citation
Metadata
- Authors
- Rees, M. G., Wincovitch, S., Schultz, J., Waterstradt, R., Beer, N. L., Baltrusch, S., Collins, F. S., & Gloyn, A. L.
- Venue
- Diabetologia
- Published
- 2011-10-25
- Volume
- 55
- Issue
- 1
- Pages
- 114-122
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2085649845
- Cited by
- 106
- References
- 6
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. https://app.cochat.ai/papers/10.1007/s00125-011-2348-5
- The paper
- Rees, M. G., Wincovitch, S., Schultz, J., Waterstradt, R., Beer, N. L., Baltrusch, S., Collins, F. S., & Gloyn, A. L. (2012). Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia. https://doi.org/10.1007/s00125-011-2348-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.